CA
NZ
UK
AU
IND
US
…
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -108.43M | -83.75M | -28.17M | -4.33M |
| Net income | -107.96M | -78.37M | -28.53M | -4.47M |
| Selling general administrative | 25.40M | 8.67M | 0.68M | 0.63M |
| Reconciled depreciation | 0.47M | 0.03M | 0.00M | 0.00M |
| Ebit | -113.14M | -67.15M | -7.05M | -4.18M |
| Ebitda | -108.43M | -72.60M | -7.05M | -4.18M |
| Depreciation and amortization | 4.71M | -5.45M | -0.00M | -0.00M |
| Non operating income net other | 4.71M | -16.50M | - | - |
| Operating income | -113.14M | -67.15M | -7.05M | -4.18M |
| Other operating expenses | 113.14M | 67.15M | 7.05M | 4.18M |
| Interest expense | 4.71M | 0.10M | 0.36M | 0.15M |
| Interest income | 4.67M | - | - | - |
| Net interest income | 4.67M | -0.10M | -0.36M | -0.15M |
| Income tax expense | -0.47M | -5.38M | 0.36M | 0.15M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 113.14M | 67.15M | 7.05M | 4.18M |
| Total other income expense net | 4.71M | -16.60M | -21.12M | -0.15M |
| Net income from continuing ops | -108.43M | -83.75M | -28.17M | -4.33M |
| Net income applicable to common shares | -108.43M | -85.30M | -28.17M | -4.33M |
| Preferred stock and other adjustments | - | 1.55M | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 277.69M | 371.40M | 291.48M | 0.24M | 0.35M |
| Other current assets | 12.12M | 12.75M | 4.44M | 0.00M | 0.04M |
| Total liab | 33.77M | 17.50M | 12.28M | 30.90M | 4.48M |
| Total stockholder equity | 243.92M | -226.22M | -117.80M | -30.65M | -4.13M |
| Other current liab | 15.51M | 9.51M | 7.62M | 0.30M | 0.27M |
| Common stock | 0.01M | 0.01M | 0.01M | - | - |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.00M | 0.00M |
| Retained earnings | -419.19M | -226.22M | -117.80M | -32.50M | -4.33M |
| Other liab | - | - | - | 16.85M | - |
| Other assets | 0.00M | 0.10M | 0.06M | - | - |
| Cash | 51.58M | 64.82M | 70.79M | 0.24M | 0.31M |
| Total current liabilities | 22.27M | 16.36M | 12.28M | 1.40M | 0.63M |
| Net debt | -39.07M | -63.26M | -70.79M | 12.40M | 3.54M |
| Short term debt | 1.00M | 0.41M | - | - | - |
| Short long term debt total | 12.51M | 1.56M | - | 12.65M | 3.85M |
| Other stockholder equity | 663.15M | 1.12M | 0.05M | 1.85M | 0.20M |
| Property plant equipment | - | 0.41M | 0.25M | - | - |
| Total current assets | 264.35M | 330.69M | 263.02M | 0.24M | 0.35M |
| Long term investments | 0.00M | 38.67M | 28.15M | - | - |
| Net tangible assets | - | 353.89M | -87.62M | -30.65M | -4.13M |
| Short term investments | 200.64M | 253.12M | 187.78M | - | - |
| Net receivables | 0.80M | 0.10M | 0.06M | - | - |
| Long term debt | - | - | - | 12.65M | 3.85M |
| Inventory | -0.80M | - | - | - | - |
| Accounts payable | 5.76M | 6.43M | 4.66M | 1.10M | 0.36M |
| Accumulated other comprehensive income | -0.05M | -1.12M | -0.06M | - | - |
| Common stock total equity | - | 0.01M | 0.01M | - | - |
| Retained earnings total equity | - | -226.22M | -117.80M | - | - |
| Non currrent assets other | 1.08M | 0.10M | 0.06M | - | - |
| Non current assets total | 13.35M | 40.71M | 28.46M | 0.00M | 0.00M |
| Capital lease obligations | 12.51M | 1.56M | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -74.66M | -216.00M | -216.00M | -216.00M |
| Change to liabilities | 3.50M | 2.44M | 0.59M | 0.36M |
| Total cashflows from investing activities | -74.93M | -214.37M | -214.37M | -214.37M |
| Net borrowings | - | 0.45M | 6.13M | 2.95M |
| Total cash from financing activities | 167.77M | 323.55M | 6.13M | 2.95M |
| Change to operating activities | -6.77M | 1.57M | 0.22M | 0.23M |
| Net income | -108.43M | -83.75M | -28.17M | -4.33M |
| Change in cash | -5.97M | 70.55M | -0.07M | 0.31M |
| Begin period cash flow | 70.79M | 0.24M | 0.31M | 0.00M |
| End period cash flow | 64.82M | 70.79M | 0.24M | 0.31M |
| Total cash from operating activities | -98.77M | -38.65M | -6.20M | -2.64M |
| Issuance of capital stock | 165.40M | 323.04M | 0.00M | 0.00M |
| Depreciation | 0.47M | 0.03M | 0.03M | 0.03M |
| Other cashflows from investing activities | - | 1.90M | - | - |
| Sale purchase of stock | 0.27M | 323.10M | - | - |
| Other cashflows from financing activities | 2.11M | 164.74M | 6.13M | 2.95M |
| Change to netincome | 16.57M | 41.05M | 21.17M | 1.09M |
| Capital expenditures | 0.28M | 0.26M | 0.26M | 0.26M |
| Cash flows other operating | -10.54M | 12.24M | - | - |
| Exchange rate changes | - | 0.01M | - | - |
| Cash and cash equivalents changes | -5.93M | 70.55M | - | - |
| Change in working capital | -5.16M | 4.02M | 0.81M | 0.59M |
| Stock based compensation | 16.57M | 2.73M | 0.04M | 0.20M |
| Other non cash items | -2.23M | 38.32M | 21.12M | 0.90M |
| Free cash flow | -99.05M | -38.91M | -6.20M | -2.64M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
| Name | Title | Year Born |
|---|---|---|
| Dr. Sheila K. Gujrathi M.D. | Exec. Chair | 1970 |
| Dr. Raju S. Mohan Ph.D. | Founder, CEO & Director | 1958 |
| Dr. John M. Nuss Ph.D. | Chief Scientific Officer | 1959 |
| Mr. Christopher W. Krueger J.D., MBA | Chief Bus. Officer | 1968 |
| Prof. William J. Sandborn M.D., Ph.D. | Pres & Chief Medical Officer | NA |
| Dr. Martin Douglas Auster M.D. | Chief Financial Officer | 1975 |
| Dr. Sheila K. Gujrathi M.D. | Executive Chairperson | 1970 |
| Dr. Raju S. Mohan Ph.D. | Founder, CEO, President & Director | 1958 |
| Mr. Christopher W. Krueger J.D., MBA | Chief Business Officer | 1968 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...